Publication date: Available online 13 November 2026 Source: Clinical Genitourinary Cancer Author(s): Matthew Cleveland, Jasmine Lee, Caiwei Zhong, Wanling Xie, Rachel Trowbridge, Daniel A. Roberts, Kerry L. Kilbridge, Bradley A. McGregor, Mary-Ellen Taplin, Alok K. Tewari, Praful Ravi, Heather Jacene, Atish D. Choudhury
Clinical utility of PSMA PET/CT imaging in patients responding to hormonal therapy for metastatic hormone-sensitive prostate cancer. // Clinical Genitourinary Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1558767326002156?dgcid=rss_sd_all
Clinical utility of PSMA PET/CT imaging in patients responding to hormonal therapy for metastatic hormone-sensitive prostate cancer. Clinical Genitourinary Cancer. https://www.sciencedirect.com/science/article/pii/S1558767326002156?dgcid=rss_sd_all
“Clinical utility of PSMA PET/CT imaging in patients responding to hormonal therapy for metastatic hormone-sensitive prostate cancer.” Clinical Genitourinary Cancer.
@article{article40992,
title = {Clinical utility of PSMA PET/CT imaging in patients responding to hormonal therapy for metastatic hormone-sensitive prostate cancer},
journal = {Clinical Genitourinary Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1558767326002156?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...